» Articles » PMID: 25918013

[Persistence of Hepatitis A Virus Antibodies After Primary Immunization and Response to Revaccination in Children and Adolescents with Perinatal HIV Exposure]

Abstract

Objective: To assess possible factors associated with the loss of antibodies to hepatitis A 7 years after the primary immunization in children of HIV-infected mothers and the response to revaccination in patients seronegative for hepatitis A.

Methods: Quantification of HAV antibodies by electrochemiluminescence was performed in 39 adolescents followed up at the Pediatric Aids Clinic of Federal University of São Paulo (Unifesp): 29 HIV-infected (HIVgroup) (median age: 12.8 years) and 10 HIV-exposed but non-infected (ENI group) (median age: 13.4 years). All of them received two doses of HAV vaccine (Havrix(®)) in 2002.

Results: The median age at primary immunization (PI) was 5.4 years for HIV group and 6.5 years for ENI group. All children, from both groups, had antibodies to HAV >20 mIU/mL after PI. Seven years later, the ENI group showed a median concentration of antibodies = 253.5 mIU/mL, while the HIV group = 113.0 mIU/mL (Mann-Whitney test, p=0.085). All ENI group and 23/29 (79.3%) from HIV group mantained HAV antibodies 7 years after PI. The levels of hepatitis A antibodies in the primary vaccination were the only factor independently associated with maintaining these antibodies for 7 years. The group that lost HAV seropositivity was revaccinated and 83.3% (5/6) responded with antibodies >20 mUI/mL.

Conclusions: The antibodies levels acquired in the primary vaccination in the HIV group were the main factor associated with antibodies loss after HAV immunization.

Citing Articles

Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus.

Tortellini E, Fosso Ngangue Y, Dominelli F, Guardiani M, Falvino C, Mengoni F Viruses. 2023; 15(9).

PMID: 37766251 PMC: 10534440. DOI: 10.3390/v15091844.


Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence.

Herzog C, Van Herck K, Van Damme P Hum Vaccin Immunother. 2020; 17(5):1496-1519.

PMID: 33325760 PMC: 8078665. DOI: 10.1080/21645515.2020.1819742.


Factors That Influence the Immune Response to Vaccination.

Zimmermann P, Curtis N Clin Microbiol Rev. 2019; 32(2).

PMID: 30867162 PMC: 6431125. DOI: 10.1128/CMR.00084-18.

References
1.
Sutcliffe C, Moss W . Do children infected with HIV receiving HAART need to be revaccinated?. Lancet Infect Dis. 2010; 10(9):630-42. DOI: 10.1016/S1473-3099(10)70116-X. View

2.
Bian G, Ma R, Dong H, Ni H, Hu F, Chen Y . Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine. 2010; 28(30):4798-801. DOI: 10.1016/j.vaccine.2010.04.096. View

3.
Kosalaraksa P, Srirompotong U, Newman R, Lumbiganon P, Wood J . Serological response to trivalent inactive influenza vaccine in HIV-infected children with different immunologic status. Vaccine. 2011; 29(16):3055-60. DOI: 10.1016/j.vaccine.2011.01.091. View

4.
Crum-Cianflone N, Wilkins K, Lee A, Grosso A, Landrum M, Weintrob A . Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis. 2011; 203(12):1815-23. PMC: 3100512. DOI: 10.1093/infdis/jir180. View

5.
Sharapov U, Bulkow L, Negus S, Spradling P, Homan C, Drobeniuc J . Persistence of hepatitis A vaccine induced seropositivity in infants and young children by maternal antibody status: 10-year follow-up. Hepatology. 2012; 56(2):516-22. DOI: 10.1002/hep.25687. View